Mr. Chair, I'll start again.
Merck's application for authorization for the antiviral drug molnupiravir is under review. Health Canada's regulatory team is using data from Merck's clinical trials to assess the benefits and risks of this product.
On June 8th, 2022. See this statement in context.
June 8th, 2022 / 5:15 p.m.
Deputy Minister, Department of Health
Mr. Chair, I'll start again.
Merck's application for authorization for the antiviral drug molnupiravir is under review. Health Canada's regulatory team is using data from Merck's clinical trials to assess the benefits and risks of this product.
See context to find out what was said next.